Literature DB >> 1606721

Increased and prolonged production of specific polymeric IgA after systemic immunization with tetanus toxoid in IgA nephropathy.

L Layward1, A C Allen, S J Harper, J M Hattersley, J Feehally.   

Abstract

IgA nephropathy (IgAN) is a chronic form of glomerulonephritis which is characterized by the deposition in the glomerular mesangium of polymeric IgA (pIgA), the source of which is unknown. In order to investigate the production of pIgA in IgAN, patients were immunized systemically with tetanus toxoid (TT). Two weeks after immunization patients and controls responded to TT with an IgA response of similar magnitude. HPLC separation of sera showed that patients with IgAN produce significantly more pIgA anti-TT than controls (7.7 versus 2.88 arbitrary units; P less than 0.04). At this time, 33% of serum IgA anti-TT produced by patients with IgAN was polymeric, compared with 21% produced by controls (P less than 0.02). Monomeric IgA (mIgA) anti-TT levels were similar in both groups. Four weeks after immunization the proportion of pIgA anti-TT in controls and patients was significantly reduced from the 2 week level (from 21% to 0%, P less than 0.02 for controls; and from 33% to 8%, P less than 0.001, for patients). Only four out of 12 controls had any detectable pIgA anti-TT at this time compared with nine out of 10 patients with IgAN (P less than 0.05), and IgAN patients produced proportionally more pIgA anti-TT than did controls (median 8%, interquartile ranges (IQR) 4-10% versus 0% IQR 0-3%; P less than 0.01). HPLC analysis under acid conditions did not alter the pattern of pIgA and mIgA anti-TT, suggesting that the high molecular weight IgA fraction was not due to complexes. These data indicate that circulating pIgA results (at least in part) from a systemic response to antigen, which may be exaggerated in IgAN.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606721      PMCID: PMC1554506          DOI: 10.1111/j.1365-2249.1992.tb06460.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Immune response to oral polio vaccine in patients with IgA glomerulonephritis.

Authors:  P O Leinikki; J Mustonen; A Pasternack
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

2.  IgA nephropathy: association of a history of macroscopic hematuria episodes with increased production of polymeric IgA.

Authors:  L Lozano; R García-Hoyo; J Egido
Journal:  Nephron       Date:  1987       Impact factor: 2.847

Review 3.  Immune mechanisms in glomerular IgA deposition.

Authors:  J Feehally
Journal:  Nephrol Dial Transplant       Date:  1988       Impact factor: 5.992

Review 4.  The commonest glomerulonephritis in the world: IgA nephropathy.

Authors:  G D'Amico
Journal:  Q J Med       Date:  1987-09

5.  Pathogenic role of polyclonal and polymeric IgA in a murine model of mesangial proliferative glomerulonephritis with IgA deposition.

Authors:  E Muso; H Yoshida; E Takeuchi; T Shimada; M Yashiro; T Sugiyama; C Kawai
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

6.  Murine bone marrow IgA responses to orally administered sheep erythrocytes.

Authors:  C D Alley; H Kiyono; J R McGhee
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

7.  Serum levels and in vitro production of IgA subclasses in patients with primary IgA nephropathy.

Authors:  A W van den Wall Bake; M R Daha; A van der Ark; P S Hiemstra; J Radl; L A van Es
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

8.  Increased rates of polymeric IgA synthesis by circulating lymphoid cells in IgA mesangial glomerulonephritis.

Authors:  J Egido; R Blasco; J Sancho; L Lozano; M Sanchez-Crespo; L Hernando
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

9.  Clearance kinetics and fate of macromolecular IgA in patients with IgA nephropathy.

Authors:  A Rifai; F P Schena; V Montinaro; M Mele; A D'Addabbo; L Nitti; J C Pezzullo
Journal:  Lab Invest       Date:  1989-10       Impact factor: 5.662

10.  Humoral immune response to influenza vaccination in patients with primary immunoglobulin A nephropathy. An analysis of isotype distribution and size of the influenza-specific antibodies.

Authors:  A W van den Wall Bake; W E Beyer; J H Evers-Schouten; J Hermans; M R Daha; N Masurel; L A van Es
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

View more
  11 in total

1.  Expression of T cell receptor variable region families by bone marrow gammadelta T cells in patients with IgA nephropathy.

Authors:  K S Buck; E M Foster; D Watson; J Barratt; I Z A Pawluczyk; J F Knight; J Feehally; A C Allen
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

2.  For further investigations in IgA nephropathy the approach from phenotype to genotype is welcome.

Authors:  F P Schena
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 3.  Pathogenesis of IgA nephropathy.

Authors:  Kar Neng Lai
Journal:  Nat Rev Nephrol       Date:  2012-03-20       Impact factor: 28.314

4.  Hyper-immunoglobulin A in the hyperimmunoglobulinemia D syndrome.

Authors:  I S Klasen; J H Göertz; G A van de Wiel; C M Weemaes; J W van der Meer; J P Drenth
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

5.  Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response.

Authors:  C Lue; A W van den Wall Bake; S J Prince; B A Julian; M L Tseng; J Radl; C O Elson; J Mestecky
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

Review 6.  Immunopathogenesis of IgAN.

Authors:  Jonathan Barratt; Alice C Smith; Karen Molyneux; John Feehally
Journal:  Semin Immunopathol       Date:  2007-09-13       Impact factor: 9.623

7.  Secretory immunoglobulin A (IgA) responses in IgA nephropathy patients after mucosal immunization, as part of a polymeric IgA response.

Authors:  J W Eijgenraam; B D Oortwijn; S W A Kamerling; J W de Fijter; A W L van den Wall Bake; M R Daha; C van Kooten
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

Review 8.  Pathogenetic significance of aberrant glycosylation of IgA1 in IgA nephropathy.

Authors:  Ichiei Narita; Fumitake Gejyo
Journal:  Clin Exp Nephrol       Date:  2008-04-12       Impact factor: 2.801

9.  Low antibody affinity restricted to the IgA isotype in IgA nephropathy.

Authors:  L Layward; A C Allen; J M Hattersley; S J Harper; J Feehally
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

Review 10.  Pathogenesis of idiopathic IgA nephropathy.

Authors:  D G Williams
Journal:  Pediatr Nephrol       Date:  1993-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.